Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.

摘要: From having been a 'single-drug not very interesting cancer type' from medical treatment perspective, of colorectal (CRC) has during the past five years become more complex issue appropriate use several cytotoxic drugs sometimes integrated with advanced metastatic surgery curative intent. The new have provided significant benefit to patients, so far mostly in setting but also adjuvant treatment. progress molecular and tumour biology produced great number 'targeted' that are now various stages clinical development. Two these drugs, monoclonal antibodies bevacizumab (Avastin) cetuximab (Erbitux), directed against VEGF EGFR, respectively, recently approved within EU for CRC. This Nordic Expert Consensus Report summarizes current status chemotherapy CRC, overviews targeted CRC and, finally, provides guidelines routine based on most available data.